CRSP - CRISPR Therapeutics AG Stock Price, Fair Value and News

56.14USD+0.58 (+1.04%)Market Closed

Market Summary

USD56.14+0.58

Market Closed

1.04%

CRSP Alerts

3 major insider sales recently.

CRSP Stock Price

View Fullscreen

CRSP RSI Chart

CRSP Valuation

Market Cap

4.5B

Price/Earnings (Trailing)

-29.04

Price/Sales (Trailing)

12.02

EV/EBITDA

-31.1

Price/Free Cashflow

-16.53

CRSP Price/Sales (Trailing)

CRSP Profitability

EBT Margin

-40.60%

Return on Equity

-8.16%

Return on Assets

-6.89%

Free Cashflow Yield

-6.05%

CRSP Fundamentals

CRSP Revenue

Revenue (TTM)

371.2M

Rev. Growth (Yr)

183.52%

Rev. Growth (Qtr)

-100%

CRSP Earnings

Earnings (TTM)

-153.6M

Earnings Growth (Yr)

180.8%

Earnings Growth (Qtr)

179.67%

Breaking Down CRSP Revenue

Last 7 days

-10.0%

Last 30 days

-22.3%

Last 90 days

-8.9%

Trailing 12 Months

7.0%

How does CRSP drawdown profile look like?

CRSP Financial Health

Current Ratio

17.54

CRSP Investor Care

Shares Dilution (1Y)

2.07%

Diluted EPS (TTM)

-1.94

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	643.1M	552.5M	461.8M	371.2M
2022	824.3M	0	0	733.7M
2021	646.9M	736.3M	825.6M	915.0M
2020	0	378.9M	468.3M	557.6M
2019	2.1M	97.9M	193.8M	289.6M
2018	31.5M	22.1M	12.6M	3.1M
2017	7.4M	10.2M	11.0M	41.0M
2016	1.2M	2.1M	3.1M	5.2M
2015	0	0	0	247.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of CRISPR Therapeutics AG

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	kulkarni samarth	acquired	374,408	19.12	19,582	chief executive officer
Apr 15, 2024	kulkarni samarth	sold	-1,173,230	59.9138	-19,582	chief executive officer
Mar 15, 2024	kulkarni samarth	acquired	764,800	19.12	40,000	chief executive officer
Mar 15, 2024	kulkarni samarth	sold	-2,899,260	72.4814	-40,000	chief executive officer
Mar 15, 2024	prasad raju	sold	-256,160	72.69	-3,524	chief financial officer
Mar 14, 2024	prasad raju	acquired	-	-	10,000	chief financial officer
Mar 12, 2024	kulkarni samarth	sold	-341,159	74.44	-4,583	chief executive officer
Mar 12, 2024	kasinger james r.	sold	-85,308	74.44	-1,146	general counsel and secretary
Mar 11, 2024	kulkarni samarth	acquired	-	-	9,000	chief executive officer
Mar 11, 2024	kulkarni samarth	sold	-767,104	78.26	-9,802	chief executive officer

Which funds bought or sold CRSP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 17, 2024	Slow Capital, Inc.	added	1.4	434,090	4,605,500	0.74%
Apr 17, 2024	Baker Chad R	unchanged	-	547,771	6,715,120	1.43%
Apr 16, 2024	Stratos Wealth Advisors, LLC	reduced	-1.19	32,580	462,329	0.03%
Apr 16, 2024	VOISARD ASSET MANAGEMENT GROUP, INC.	unchanged	-	1,112	13,632	0.01%
Apr 16, 2024	Harbour Capital Advisors, LLC	reduced	-2.31	4,192	275,077	0.07%
Apr 16, 2024	Thrive Wealth Management, LLC	new	-	211,296	211,296	0.04%
Apr 16, 2024	FLAGSHIP HARBOR ADVISORS, LLC	reduced	-0.65	33,741	446,651	0.03%
Apr 16, 2024	MCF Advisors LLC	new	-	1,364	1,364	-%
Apr 16, 2024	LINCOLN CAPITAL CORP	new	-	204,480	204,480	0.09%
Apr 16, 2024	COUNTRY TRUST BANK	unchanged	-	2,780	34,080	-%

Are Funds Buying or Selling CRSP?

Are funds buying CRSP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CRSP

No. of Funds

CRSP Alerts

3 major insider sales recently.

Unveiling CRISPR Therapeutics AG's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	capital international investors	10.2%	8,223,994	SC 13G/A
Feb 12, 2024	nikko asset management americas, inc.	4.24%	3,369,762	SC 13G/A
Feb 09, 2024	capital international investors	8.1%	6,420,736	SC 13G/A
Feb 05, 2024	sumitomo mitsui trust holdings, inc.	4.24%	3,369,762	SC 13G/A
Jan 29, 2024	ark investment management llc	10.75%	8,536,104	SC 13G/A
Jan 10, 2024	ark investment management llc	10.75%	8,536,104	SC 13G/A
Apr 11, 2023	ark investment management llc	10.16%	7,990,188	SC 13G/A
Feb 13, 2023	capital international investors	7.1%	5,560,492	SC 13G
Feb 10, 2023	nikko asset management americas, inc.	5.11%	4,006,476	SC 13G/A
Feb 10, 2023	ark investment management llc	10.00%	7,829,932	SC 13G/A

Recent SEC filings of CRISPR Therapeutics AG

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	4	Insider Trading
Apr 15, 2024	144	Notice of Insider Sale Intent
Apr 10, 2024	SC 13G/A	Major Ownership Report
Apr 09, 2024	ARS	ARS
Apr 09, 2024	DEF 14A	DEF 14A
Apr 09, 2024	DEFA14A	DEFA14A
Mar 27, 2024	PRE 14A	PRE 14A
Mar 22, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading

Peers (Alternatives to CRISPR Therapeutics AG)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.5B	6.8B	-0.79%	-27.48%	-8.38	5.77	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-1.45%	-27.97%	-41.56	10.01	76.23%	61.08%
BMRN	17.1B	2.4B	7.98%	-8.04%	101.85	7.06	15.42%	18.43%
INCY	11.8B	3.7B	-8.07%	-28.58%	19.8	3.2	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-14.74%	-41.61%	-10.96	14.6	425.83%	18.94%
BBIO	4.4B	-	-10.03%	65.15%	-6.72	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-3.97%	-4.38%	-13.8	12.2	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.12%	-12.78%	-46.22	3.9	40.45%	71.62%
ARWR	2.8B	240.7M	-19.94%	-25.89%	-9.4	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.9B	398.2M	-0.50%	-10.21%	26.41	4.74	85.90%	-14.05%
NVAX	544.4M	983.7M	-24.32%	-58.17%	-1	0.55	-50.36%	17.16%
CRBP	389.6M	881.7K	-10.79%	209.42%	-8.73	466.16	-77.61%	-5.33%
INO	258.5M	4.9M	3.17%	4.73%	-1.91	53.11	-54.97%	51.71%
IBIO	6.6M	2.1M	79.05%	74.07%	-0.24	2.14	-13.45%	66.37%

CRISPR Therapeutics AG News

Latest updates

CRISPR Therapeutics AG Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1
Revenue	-	201,206,000	-	70,000,000	100,000,000	70,966,333	41,932,667	12,899,000	824,000	900,701,000	735,964,000	571,227,000	406,490,000	241,753,000	77,016,000	211,928,000	106,128,000	328,000	115,000	563,000	1,088,000	16,706,500
Operating Expenses	-0.6%	131,623,000	132,411,000	165,223,000	164,487,000	131,547,000	176,912,000	158,597,000	129,673,000	138,083,000	115,082,000	108,131,000	92,547,000	80,733,000	66,033,000	72,765,000	55,301,000	48,751,000	45,343,000	49,995,000	38,374,000	28,355,000
S&GA Expenses	-9.9%	16,479,000	18,291,000	19,032,000	22,360,000	21,169,000	28,021,000	23,168,000	23,709,000	28,806,000	24,517,000	23,305,000	21,539,000	21,353,000	17,272,000	15,519,000	15,768,000	14,929,000	16,542,000	10,175,000	12,741,000	8,836,000
R&D Expenses	4.9%	95,144,000	90,698,000	101,555,000	99,935,000	103,555,000	118,245,000	103,605,000	83,500,000	82,332,000	70,620,000	36,801,000	71,008,000	59,380,000	48,761,000	57,246,000	39,533,000	33,822,000	28,801,000	39,820,000	25,633,000	19,519,000
EBITDA Margin	52.0%	-0.35	-0.74	-0.44	-0.55	-0.68	0.37	0.43	1.49	1.60	-1.32	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-46.1%	222,000	412,000	900,000	1,320,000	-9,450,500	3,600,000	-2,232,500	-595,000	4,100,000	600,000	-169,000	200,000	400,000	26,000	274,000	85,000	85,000	234,000	137,000	96,000	86,000
Earnings Before Taxes	180.2%	89,580,000	-111,740,000	-76,817,000	-51,745,000	-120,051,000	-175,609,000	-143,501,000	-127,748,000	763,368,000	-112,588,000	-107,186,000	-92,239,000	-79,277,000	30,546,000	138,697,000	-53,614,000	-48,323,000	-47,356,000	-50,574,000	-38,284,000	-28,214,000
EBT Margin	48.0%	-0.41	-0.78	-0.46	-0.58	-0.71	0.35	0.41	1.44	1.56	-1.35	-	-	-	-	-	-	-	-	-	-	-
Net Income	179.7%	89,347,000	-112,152,000	-77,740,000	-53,065,000	-110,575,000	-179,217,000	-141,248,000	-127,153,000	759,225,000	-113,163,000	-107,039,000	-92,439,000	-79,656,000	30,542,000	138,423,000	-53,699,000	-48,408,000	-47,590,000	-50,711,000	-38,380,000	-
Net Income Margin	45.9%	-0.41	-0.77	-0.45	-0.57	-0.71	0.34	0.41	1.42	1.54	-1.35	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-130.6%	-96,811,000	-41,974,000	-136,800,000	5,740,000	-119,519,000	-150,589,000	-95,221,000	-118,378,000	778,553,000	-107,687,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	6.8%	2,230	2,087	2,197	2,244	2,243	2,353	2,463	2,606	2,752	2,822	2,900	1,958	1,828	1,485	1,047	1,007	1,067	721	494	498	489
Current Assets	8.4%	1,908	1,761	1,860	1,908	1,853	1,933	2,107	2,261	2,418	2,519	2,621	1,832	1,717	1,391	966	929	988	664	438	450	466
Cash Equivalents	-26.2%	389	528	445	344	212	494	497	684	923	1,012	1,647	1,126	1,169	1,041	945	890	944	630	428	438	457
Net PPE	-2.7%	152	156	159	162	164	166	165	157	138	106	75.00	52.00	42.00	38.00	34.00	32.00	31.00	21.00	20.00	19.00	19.00
Liabilities	-3.4%	347	359	381	389	368	399	373	361	352	309	296	152	164	142	136	121	127	129	127	118	97.00
Current Liabilities	-2.2%	109	111	133	147	121	151	120	114	120	96.00	100	83.00	94.00	84.00	75.00	55.00	57.00	80.00	31.00	28.00	28.00
Shareholder's Equity	9.0%	1,883	1,728	1,816	1,855	1,875	1,954	2,091	2,245	2,399	2,513	2,604	1,805	1,664	1,343	911	886	939	592	368	380	392
Retained Earnings	8.2%	-999	-1,089	-976	-899	-846	-735	-560	-375	-195	-54.67	72.00	-686	-573	-466	-374	-294	-224	-255	-393	-339	-291
Additional Paid-In Capital	2.0%	2,878	2,821	2,799	2,761	2,735	2,709	2,670	2,635	2,598	2,566	2,530	2,490	2,236	1,808	1,283	1,179	1,162	846	760	718	682
Shares Outstanding	0.8%	80.00	79.00	79.00	79.00	79.00	78.00	78.00	77.00	76.00	76.00	75.00	75.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	4,100	-	-	-	4,300	-	-	-	11,400	-	-	-	4,500	-	-	-	2,500	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-141.1%	-96,073	-39,856	-133,245	8,799	-113,328	-105,218	-141,956	-135,239	-86,038	-81,329	807,002	-100,663	-81,212	-75,700	-29,279	-52,175	3,376	133,420	-36,382	-43,737	-28,372
Share Based Compensation	-7.8%	18,420	19,968	21,765	20,875	22,805	24,545	24,852	25,745	25,768	26,199	28,331	22,092	18,930	17,240	15,697	14,151	11,857	11,343	11,186	9,671	13,025
Cashflow From Investing	-167.1%	-81,453	121,348	216,923	117,829	-175,532	87,464	-56,072	-114,515	-8,716	-565,180	-293,636	-167,898	-204,244	-330,330	-3,605	-2,991	7,057	-2,461	-2,174	-1,097	-1,000
Cashflow From Financing	2402.5%	38,939	1,556	16,765	5,404	2,478	15,112	10,353	10,649	6,299	10,212	8,443	225,991	412,627	512,888	89,505	1,132	304,718	70,885	29,654	25,726	-1,269

CRSP Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 371,206	$ 1,198	$ 914,963
Operating expenses:
Research and development	387,332	461,645	340,567
General and administrative	76,162	102,464	99,690
Collaboration expense, net	130,250	110,250	101,178
Total operating expenses	593,744	674,359	541,435
(Loss) income from operations	(222,538)	(673,161)	373,528
Other income
Other income, net	71,816	22,661	6,003
Total other income, net	71,816	22,661	6,003
Net income (loss) before income taxes	(150,722)	(650,500)	379,531
(Provision) benefit for income taxes	(2,888)	325	(1,870)
Net (loss) income	(153,610)	(650,175)	377,661
Foreign currency translation adjustment	73	(80)	(11)
Unrealized gain (loss) on marketable securities	17,487	(10,500)	(4,973)
Comprehensive (loss) income	$ (136,050)	$ (660,755)	$ 372,677
Net (loss) income per common share - basic	$ (1.94)	$ (8.36)	$ 4.97
Basic weighted-average common shares outstanding	79,220,930	77,746,575	75,948,686
Net (loss) income per common share - diluted	$ (1.94)	$ (8.36)	$ 4.7
Diluted weighted-average common shares outstanding	79,220,930	77,746,575	80,393,496
Collaboration Revenue [Member]
Revenue:
Total revenue	$ 370,000	$ 436	$ 913,081
Grant Revenue [Member]
Revenue:
Total revenue	$ 1,206	$ 762	$ 1,882

CRSP Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 389,477	$ 211,885
Marketable securities	1,304,215	1,603,433
Accounts receivable	200,000	0
Prepaid expenses and other current assets	14,386	37,708
Total current assets	1,908,078	1,853,026
Property and equipment, net	151,945	163,634
Marketable securities, non-current	1,973	53,130
Intangible assets, net	16	71
Restricted cash	11,591	11,635
Operating lease assets	153,993	156,921
Other non-current assets	1,975	4,640
Total assets	2,229,571	2,243,057
Current liabilities:
Accounts payable	38,147	27,428
Accrued expenses	45,335	77,682
Deferred revenue, current	4,105	0
Accrued tax liabilities	438	135
Operating lease liabilities	15,625	15,842
Other current liabilities	5,141	20
Total current liabilities	108,791	121,107
Deferred revenue, non-current	14,012	12,323
Operating lease liabilities, net of current portion	223,007	228,179
Other non-current liabilities	958	5,969
Total liabilities	346,768	367,578
Commitments and contingencies (Note 9)
Shareholders’ equity:
Common shares, CHF 0.03 par value, 126,536,183 and 150,347,467 shares authorized at December 31, 2023 and 2022, respectively, 80,214,694 and 78,692,766 shares issued at December 31, 2023 and 2022, respectively, 80,044,378 and 78,512,450 shares outstanding at December 31, 2023 and 2022,respectively	2,497	2,441
Treasury shares, at cost, 170,316 and 180,316 shares at December 31, 2023 and 2022, respectively	(62)	(63)
Additional paid-in capital	2,878,155	2,734,838
Accumulated deficit	(999,700)	(846,090)
Accumulated other comprehensive income (loss)	1,913	(15,647)
Total shareholders’ equity	1,882,803	1,875,479
Total liabilities and shareholders’ equity	$ 2,229,571	$ 2,243,057

About CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CEO	Dr. Samarth Kulkarni Ph.D.
WEBSITE	crisprtx.com
INDUSTRY	Biotechnology
EMPLOYEES	458

CRISPR Therapeutics AG Frequently Asked Questions

What is the ticker symbol for CRISPR Therapeutics AG? What does CRSP stand for in stocks?

CRSP is the stock ticker symbol of CRISPR Therapeutics AG. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CRISPR Therapeutics AG (CRSP)?

As of Wed Apr 17 2024, market cap of CRISPR Therapeutics AG is 4.46 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRSP stock?

You can check CRSP's fair value in chart for subscribers.

What is the fair value of CRSP stock?

You can check CRSP's fair value in chart for subscribers. The fair value of CRISPR Therapeutics AG is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CRISPR Therapeutics AG is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRSP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CRISPR Therapeutics AG a good stock to buy?

The fair value guage provides a quick view whether CRSP is over valued or under valued. Whether CRISPR Therapeutics AG is cheap or expensive depends on the assumptions which impact CRISPR Therapeutics AG's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRSP.

What is CRISPR Therapeutics AG's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, CRSP's PE ratio (Price to Earnings) is -29.04 and Price to Sales (PS) ratio is 12.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRSP PE ratio will change depending on the future growth rate expectations of investors.